Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Precigen, Inc. (NASDAQ: PGEN), formerly known as Intrexon Corporation until its rebranding in 2020, is a clinical-stage biopharmaceutical company pioneering the future of gene and cell therapies. Precigen is dedicated to developing and commercializing transformative therapies for patients with cancer, autoimmune disorders, and infectious diseases. The company leverages its innovative technology platforms, including the UltraCAR-T® platform for CAR-T therapies and the AdenoVerse™ platform for immunotherapies and therapeutic vaccines, to advance a pipeline of novel treatments. The strategic shift from Intrexon's broader synthetic biology focus to Precigen's dedicated biopharmaceutical approach aimed to streamline operations and concentrate on high-value clinical assets.
The headquarters serves as the central hub for corporate strategy, research and development leadership, clinical operations management, and administrative functions.
The facility likely includes advanced laboratory spaces for gene and cell therapy research, process development, and potentially cGMP-compliant manufacturing capabilities for clinical trial materials. It's designed to foster collaboration and innovation.
Precigen's work culture is expected to be science-driven, innovative, and patient-focused, with an emphasis on collaboration, agility, and achieving breakthroughs in complex diseases. Employees are likely motivated by the potential to make a significant impact on patients' lives.
The Germantown headquarters is significant as it centralizes Precigen's efforts in pioneering next-generation gene and cell therapies, placing it within a prominent U.S. biotechnology corridor with access to talent and research institutions.
Precigen's primary operational footprint is in North America (USA) and Europe (Belgium). While its physical offices are concentrated, its clinical trials and collaborations often have a global reach, involving sites and partners in various countries to advance its therapeutic candidates through development and towards potential commercialization worldwide.
20374 Seneca Meadows Parkway, Suite 100
Germantown
Maryland
USA
Address: Technologiepark Zwijnaarde 82, 9052 Gent, Belgium (Address for ActoBio Therapeutics, a Precigen company)
Serves as a key European hub for Precigen's research and development in specific therapeutic areas, leveraging local expertise and infrastructure for advancing its innovative AG-based pipeline.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Intrexon Corporation' leadership includes:
Intrexon Corporation has been backed by several prominent investors over the years, including:
Precigen's executive leadership team has shown stability. Recent public announcements focus more on clinical and financial updates rather than major executive turnover. Any significant changes are typically filed with the SEC.
Discover the tools Intrexon Corporation uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Precigen likely uses standard corporate email formats. The most common patterns for companies of its size and type involve combinations of first name, last name, and initials.
[first_initial][last]@precigen.com
Format
hhsabzevari@precigen.com
Example
80%
Success rate
Precigen Press Release • March 5, 2024
Precigen provided financial results for Q4 and full year 2023, along with updates on its clinical pipeline, including advancements in its UltraCAR-T and AdenoVerse platforms....more
Precigen Press Release • February 20, 2024
Precigen announced the publication of positive Phase 1/2 data for its PRGN-2012 AdenoVerse immunotherapy in recurrent respiratory papillomatosis (RRP) in The Lancet eBioMedicine, highlighting its potential as a transformative treatment....more
Precigen Press Release • January 8, 2024
Precigen announced its participation in the J.P. Morgan Healthcare Conference, where CEO Helen Sabzevari provided a corporate update and outlined strategic priorities for 2024....more
Precigen Press Release • November 7, 2023
Precigen shared its Q3 2023 financial performance and progress across its therapeutic programs, emphasizing upcoming clinical milestones....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Intrexon Corporation, are just a search away.